Patrys Limited has released a press release.
Patrys Secures 50% Revenue Share in IP Commercialisation
Earlier from Patrys
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
- Appendix 4C - Quarterly - 31 March 2026
- $3.2 million Placement to Advance Clinical Trials
- Investor Presentation - Broker Meets Biotech